Red cell requirements for intensive care units adhering to evidence‐based transfusion guidelines

Walsh, Timothy; Garrioch, M.; Maciver, Caroline R.; Lee, Robert J.; MacKirdy, Fiona; McClelland, D. B. L.; Kinsella, John; Wallis, Charles

doi:10.1111/j.1537-2995.2004.04085.x

Cited by 82 publications

(75 citation statements)

References 15 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(5) Yet, in the Eastern Europe and Scotland, the rates were 37% and 39.5%, respectively. (10,14,18) These rates are similar to other studies conducted in Brazil, 35%. (21,22) The transfusion rate for the patients in the HNSC study was 19,33%.…”

Section: Discussionsupporting

confidence: 86%

“…(14) The mean in our samples was 0.44 red blood In a study involving Canada researchers, among the pre-transfusion diagnosis for red blood cells transfusion, the circulatory system diseases were predominant (28%), followed by polytrauma (20%) and sepsis (6%). (10) In the study by Vicent et al, prevailed the coronary ischemic diseases (18.2%), circulatory system diseases (16.5%) and respiratory system diseases (15.6%).…”

Section: Discussionmentioning

confidence: 70%

“…Thus, blood transfusions are often prescribed during the ICU stay. (14)(15)(16)(17)(18)(19) With this treatment it is expected to improve the tissues oxygenation, preventing organic dysfunction development. However, recent studies have shown that blood transfusion is not effective in sepsis patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Transfusão de concentrado de hemácias na unidade de terapia intensiva

Volpato¹,

Ferreira²,

Ferreira³

et al. 2009

Rev. bras. ter. intensiva

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Transfusão de concentrado de hemácias na unidade de terapia intensiva

Volpato¹,

Ferreira²,

Ferreira³

et al. 2009

Rev. bras. ter. intensiva

View full text Add to dashboard Cite

“…11,12 Second, RBC transfusion is one of the most common therapeutic interventions in the ICU; 11 30-50% of all patients receive at least one RBC transfusion during their ICU stay, and a significant number receive RBC transfusions during the pre-and post-ICU hospital stay; in the UK, 10% of all RBCs are transfused to patients in general ICUs. 13 Third, there is strong evidence from a previous landmark trial [the Transfusion Requirements in Critical Care (TRICC) trial] 14 that a restrictive haemoglobin transfusion trigger is safe for most critically ill patients. As a result, the use of RBCs is more consistent in the critically ill, which decreases the potential confounding effect of wide variation in RBC use among similar patient groups.…”

Section: Introductionmentioning

confidence: 99%

The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost–utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up

Walsh

Stanworth

Boyd

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

on behalf of the UK ABLE trial investigatorsThe Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 09/144/51. The contractual start date was in September 2011. The draft report began editorial review in September 2016 and was accepted for publication in April 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the int...

show abstract

“…Therefore, clinicians continue to provide ''appropriate'' transfusion therapy by avoiding these extremes and balancing the riskbenefit ratio in favor of optimal transfusion practice for each patient. While undertransfusion has not been frequently reported in the literature, global application of transfusion thresholds derived from previous randomized trials in critical care (TRICC) has contributed to lowering transfusion thresholds in critical care patients [1,2]. Conversely, overtransfusion has received considerable attention.…”

mentioning

confidence: 99%